ZIMURA in Combination With Eylea in Patients With Idiopathic Polypoidal Choroidal Vasculopathy (IPCV)
Status:
Withdrawn
Trial end date:
2019-12-01
Target enrollment:
Participant gender:
Summary
To asses the safety of intravitreal Zimura™ (complement factor C5 inhibitor) administered in
combination with Eylea® in treatment experienced subjects with idiopathic polypoidal
choroidal vasculopathy